Drugs / Haemophilus influenzae type a (Hia) glycoconjugate vaccine
Haemophilus influenzae type a (Hia) glycoconjugate vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06465420 Comparator | May → Oct 2024 overdue | haemophilus meningitis | InventVacc Biologicals Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Haemophilus influenzae type a (Hia) glycoconjugate vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06465420 ↗ |
| Modality | Vaccine | “novel glycoconjugate candidate vaccine” NCT06465420 ↗ |
| Route | Intramuscular | “0.5 mL intramuscular injection, given on days 0 and 28” NCT06465420 ↗ |